News
ISEE
--
0.00%
--
Iveric Bio to Present at the Cowen 41st Annual Health Care Conference
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, and Pravin U. Dugel, M.D., Chief Strategy...
BusinessWire - BZX · 1d ago
Press Release: Iveric Bio to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on Wednesday, March 3, 2021
Dow Jones · 2d ago
15 Best Micro-Cap Stocks to Buy Now
In this article, we will discuss the 15 Best Micro-Cap Stocks to Buy Now. You can skip our discussion of the merits of investing in micro-cap stocks and go directly to 5 Best Micro-Cap Stocks to Buy Now. A micro-cap stock has a market capitalization betwee...
Insider Monkey · 02/16 18:27
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11)
Benzinga · 02/11 12:26
10 Best Small-Cap Biotech Stocks Under $10 in 2021
In this article we will list the 10 best small-cap biotech stocks under $10 in 2021. Click to skip ahead and see the 5 Best Small-Cap Biotech Stocks Under $10 in 2021. We like healthcare and technology industries because of their above-average long-term gr...
Insider Monkey · 02/08 15:11
IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IVERIC bio granted non-statutory stock options to purchase an aggregate of 28,000 shares of common stock to two newly hired, non-executive employees.
Business Wire · 01/05 13:00
IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IVERIC bio granted non-statutory stock options to purchase an aggregate of 28,000 shares of common stock to two newly hired, non-executive employees.
Business Wire · 01/05 13:00
IVERIC bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
Business Wire · 12/17/2020 13:00
IVERIC bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
IVERIC bio announced that Glenn P. Sblendorio, CEO and President, will present at the 39th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2021.
Business Wire · 12/17/2020 13:00
IVERIC bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 39th Annual J.P. Morgan Healthcare Conference in a virtual session on Thursday, January 14, 2021...
BusinessWire · 12/17/2020 10:00
IVERIC bio to Present at the 39th Annual J.P. Morgan Healthcare Conference
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 39th Annual J.P. Morgan Healthcare Conference in a virtual session on Thursday, January 14, 2021...
BusinessWire · 12/17/2020 10:00
IVERIC bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
IVERIC bio granted a newly hired employee a non-statutory stock option to purchase 34,000 shares of the Company’s common stock.
Business Wire · 12/04/2020 13:00
Family Vision Practice Merges with Sterling Vision
, /PRNewswire/ -- Sterling Vision is pleased to announce the addition of Family Vision Practice to our network. Family Vision Practice is located in , and has been the practice of Dr. for the past 39 years. "I have selected Sterling Vision to assume my practice effective so I can work part-time as a deacon at the St. Anthony of Padua Catholic Church," says Dr. Krebsbach. "I am confident that the Sterling Vision team will create a friendly and professional atmosphere that my patients can rely on for all of their eye health needs."
PR Newswire - PRF · 11/12/2020 16:00
Family Vision Practice Merges with Sterling Vision
, /PRNewswire/ -- Sterling Vision is pleased to announce the addition of Family Vision Practice to our network. Family Vision Practice is located in , and has been the practice of Dr. for the past 39 years. "I have selected Sterling Vision to assume my p...
PR Newswire - PRF · 11/12/2020 16:00
Family Vision Practice Merges with Sterling Vision
, /PRNewswire/ -- Sterling Vision is pleased to announce the addition of Family Vision Practice to our network. Family Vision Practice is located in , and has been the practice of Dr. for the past 39 years. "I have selected Sterling Vision to assume my p...
PR Newswire - PRF · 11/12/2020 16:00
Family Vision Practice Merges with Sterling Vision
, /PRNewswire/ -- Sterling Vision is pleased to announce the addition of Family Vision Practice to our network. Family Vision Practice is located in , and has been the practice of Dr. for the past 39 years. "I have selected Sterling Vision to assume my p...
PR Newswire - PRF · 11/12/2020 16:00
Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 11/03/2020 12:45
Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 11/03/2020 12:45
Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation
Simply Wall St. · 11/03/2020 12:45
Here's Why We're Not Too Worried About IVERIC bio's (NASDAQ:ISEE) Cash Burn Situation
Simply Wall St. · 11/03/2020 12:45
Webull provides a variety of real-time ISEE stock news. You can receive the latest news about IVERIC bio Inc through multiple platforms. This information may help you make smarter investment decisions.
About ISEE
IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovering and developing of treatment options for retinal diseases. The Company is developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases (IRDs). The Company’s therapeutics portfolio consists of its clinical stage product candidate Zimura (avacincaptad pegol), a complement C5 inhibitor, and IC-500, its preclinical product candidate from its High temperature requirement A serine peptidase one protein (HtrA1), inhibitors program. Its lead gene therapy products also includes IC-100 and IC-200.